Compare GSK plc (GSK) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? GSK plc trades at $52.74 (market cap $101.34B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $49.64. The key difference: GSK plc pays a 3.49% dividend while Vanguard Sht-Term Inflation-Protected Sec Idx ETF pays none, and GSK plc is trading nearer its 52-week high, Vanguard Sht-Term Inflation-Protected Sec Idx ETF nearer its low. Which is the better fit depends on your goals.
| GSK | VTIP | |
|---|---|---|
Market Cap | $101.34B | — |
Sector | Health | — |
52-Week High | $61.18 | $50.75 |
52-Week Low | $36.20 | $49.39 |
Enterprise Value | $121.95B | — |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK's stock trades at $51.25, down 1.99% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 17.78% net margin and 36.42% ROE, supported by a consistent earnings beat history. Recent positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline progress. Valuation appears reasonable with a P/E of 13.71 and EV/EBITDA of 9.16.
The outlook balances a solid core business and promising oncology pipeline against a mixed analyst consensus and near-term cash flow pressures. Key opportunities lie in execution of new drug launches and the upcoming CEO strategy update, while risks include clinical trial setbacks, competitive pressures, and integration of potential acquisitions like Nuvalent.
VTIP, the Vanguard Short-Term Inflation-Protected Securities ETF, trades at $49.63, showing minimal daily movement. Technical indicators are bearish overall, with moving averages signaling a downtrend. Recent news highlights its role as an inflation hedge, with institutional buying interest noted. Financial ratios are not applicable as it is a bond ETF tracking TIPS.
The outlook for VTIP is tied to inflation trends and Federal Reserve policy. It offers protection against rising prices but faces headwinds if inflation moderates or rates stay high. Current sentiment is cautious, with the ETF positioned for investors seeking inflation-adjusted income in a volatile market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
